USPTO Art Unit 1623 Prosecution Statistics

Art Unit Information

Art Unit: 1623
Group: 1620
Tech Center: 1600
Total Cases: 12,504
Last Active: December 2024

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19000200KRAS G12D MODULATING COMPOUNDSDecember 2024May 2025Allow511YesNo
18986415Method of treating post-traumatic stress disorder with carpipramineDecember 2024March 2025Allow300YesNo
18941779USES OF A CO-CRYSTAL OF PSILOCYBIN AND PSILOCINNovember 2024March 2025Allow401YesNo
18888371SOLID PSILOCIN SALTSSeptember 2024April 2025Allow711NoNo
18885140FATTY ACID COMPOSITIONSSeptember 2024April 2025Allow722YesNo
18826887PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOFSeptember 2024November 2024Allow200YesNo
18778172GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PHJuly 2024September 2024Allow200NoNo
18751006PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024October 2024Abandon410NoNo
18743944Use of Deuterated Empathogens as Therapeutic AgentsJune 2024September 2024Allow301YesNo
18718086USE OF FLIBANSERIN IN PREPARATION OF DRUG FOR TREATING ANDROGENIC ALOPECIAJune 2024November 2024Allow601YesNo
18663460INHIBITING MONOACYLGLYCEROL LIPASE (MAGL)May 2024November 2024Allow610NoNo
18660815CD73 INHIBITORSMay 2024June 2025Allow1401NoNo
18654709METHOD OF TREATING MIDDLE EAST RESPIRATORY SYNDROME (MERS)May 2024December 2024Allow710YesNo
18705978SHP2 AND CDK4/6 DUAL-TARGET INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAMEApril 2024January 2025Allow901YesNo
18648414METHOD FOR EXTRACTING CHONDROITIN SULFATE FROM EGGSHELL MEMBRANEApril 2024June 2024Allow100NoNo
186348651-(NAPHTHALEN-2-YLOXY)-3-(PIPERIDIN-1-YL)PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)April 2024September 2024Allow510NoNo
18632991Acyclic Thiol ProdrugsApril 2024May 2025Abandon1301NoNo
18631828CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHODApril 2024June 2025Abandon1401NoNo
18605925PROCESS FOR THE PREPARATION OF HIGH PURITY NORBORNENE SILYL ETHERSMarch 2024April 2025Allow1320YesNo
18594323TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORSMarch 2024April 2025Abandon1310NoNo
18688333NOVEL SALT OF 2-AMINO-2-(2-(1-DECYL-1H-1,2,3-TRIAZOL-4-YL)ETHYL)PROPANE-1,3-DIOL, AND PHARMACEUTICAL COMPOSITION CONTAINING SAMEFebruary 2024May 2025Allow1420NoNo
18439896METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER USING SALVIANOLIC ACID BFebruary 2024April 2025Allow1410NoNo
184363582,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA 3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024July 2024Allow500NoNo
18431308POTENTIATION OF HELMINTH TREATMENTFebruary 2024April 2025Abandon1410NoNo
18427164RAD51 INHIBITORSJanuary 2024May 2025Abandon1610NoNo
184259612-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AS AN ANTIMICROBIAL COMPOUNDJanuary 2024August 2024Allow710NoNo
184259702-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AS AN ANTIMICROBIAL COMPOUNDJanuary 2024August 2024Allow720NoNo
18421660ANTHELMINTIC HETEROCYCLIC COMPOUNDSJanuary 2024January 2025Allow1210NoNo
18417867N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024September 2024Allow800NoNo
18414679POLYANIONIC ACIDS TO IMPROVE RECOVERY AND MINIMIZE SYSTEM LOSSJanuary 2024March 2025Allow1401YesNo
18405058DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDSJanuary 2024January 2025Allow1311NoNo
18403360STERICALLY STABILIZED CARRIER COMPOSITIONS FOR TREATING A MAMMALJanuary 2024November 2024Allow1101NoNo
184025386-[4,4-BIS(4-BROMOPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]HEXANOIC ACID AS AN ANTIMICROBIAL COMPOUNDJanuary 2024October 2024Allow1030NoNo
183984804-[4,4-BIS(4-BROMOPHENYL)-5-OXO-2-THIOXOIMIDAZOLIDIN-1-YL]BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUNDDecember 2023October 2024Allow1030NoNo
18399599LYOPHYLLUM DECASTES POLYSACCHARIDE, PREPARATION METHOD AND APPLICATION THEREOFDecember 2023April 2024Allow410NoNo
18393818METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOFDecember 2023October 2024Abandon1010NoNo
18529117SALTS AND CRYSTAL FORMS OF GABA-A POSITIVE ALLOSTERIC MODULATORDecember 2023May 2025Allow1710NoNo
18528691APPARATUS FOR TREATING BENIGN PROSTATIC HYPERPLASIADecember 2023June 2024Allow610YesNo
18522440METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBINNovember 2023June 2025Allow1901NoNo
18519337METHOD OF PREPARING IONIC FLUIDSNovember 2023June 2025Allow1930NoYes
18520195FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGSNovember 2023May 2024Allow610NoNo
18517380CRYSTALLINE SOLIDS OF NICOTINIC ACID MONONUCLEOTIDE AND ESTERS THEREOF AND METHODS OF MAKING AND USENovember 2023February 2024Allow300YesNo
18515734TREATING PAIN ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHYNovember 2023October 2024Allow1110NoNo
18511973NUCLEOSIDE PHOSPHORAMIDATE PRODRUGSNovember 2023April 2024Allow510NoNo
18388765Benzimidazoles and Methods of Using SameNovember 2023November 2024Allow1210NoNo
18504672DEUTERATED COMPOUNDS AND USES THEREOFNovember 2023November 2024Allow1211NoNo
18502972GLP-1R MODULATING COMPOUNDSNovember 2023June 2025Allow1911NoNo
18502396STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINENovember 2023May 2024Allow710YesNo
18385766COMPOSITIONS AND DOSAGE FORMS FOR TREATMENT OF HPV INFECTION AND HPV-INDUCED NEOPLASIAOctober 2023December 2024Allow1320YesNo
18385778TREATMENT OF HPV-INDUCED NEOPLASIAOctober 2023January 2025Abandon1511NoNo
18495012NICOTINE FORMULATIONOctober 2023November 2024Abandon1310NoNo
18494382C1-SUBSTITUTED ISOPROPYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVESOctober 2023September 2024Allow1121YesNo
18491943METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATIONOctober 2023October 2024Allow1210NoNo
18491021N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELSOctober 2023November 2024Allow1310NoNo
18487134BIOLOGICAL DESULFURIZER FOR REMOVING ORGANIC SULFUR IN FRACTURING FLOWBACK FLUID AND APPLICATION THEREOFOctober 2023January 2024Allow300NoNo
183788626-(6-BROMO-2-OXO-2H-CHROMEN-3-YL)-4-(3-BROMOPHENYL)-2- ALKOXYNICOTINONITRILE AS ANTIMICROBIAL COMPOUNDSOctober 2023October 2024Allow1330NoNo
18482475ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOFOctober 2023January 2025Abandon1601NoNo
18376981THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USEOctober 2023May 2025Allow1910NoNo
18481787COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITYOctober 2023November 2024Abandon1310NoNo
18376339INJECTABLE IBUPROFEN FORMULATIONOctober 2023May 2025Abandon2020NoNo
18479185THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USEOctober 2023October 2024Allow1200NoNo
18374543Oligosaccharide Compound for Inhibiting Intrinsic Coagulation Factor X-Enzyme Complex, and Preparation Method Therefor and Uses ThereofSeptember 2023December 2024Allow1511YesNo
18373980USE OF BAICALIN IN PREPARATION OF DRUG FOR TREATING TUMOR IRRESPONSIVE TO IMMUNE CHECKPOINT INHIBITORS (ICIs)/UNDERGOING HYPERPROGRESSIONSeptember 2023April 2024Allow720YesNo
18477050GLP-1 RECEPTOR AGONISTS AND USES THEREOFSeptember 2023January 2025Allow1610NoNo
18373423Method for Chemically Synthesizing Helicobacter pylori Core Lipopolysaccharide Oligosaccharide Antigen Carbohydrate ChainSeptember 2023April 2024Allow610YesNo
18373702COMPOUNDS AND USES THEREOFSeptember 2023November 2024Allow1410NoNo
18476249FUSED PYRROLINES WHICH ACT AS UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) INHIBITORSSeptember 2023December 2024Abandon1401NoNo
18474108IMMUNOREGULATORY MICROPARTICLES FOR MODULATING INFLAMMATORY ARTHRITIDESSeptember 2023September 2024Allow1220YesNo
18372417TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOFSeptember 2023March 2024Allow511NoNo
18472048Intravenous Ganaxolone Formulations and Methods of Use in Treating Status Epilepticus and Other Seizure DisordersSeptember 2023July 2024Abandon1010NoNo
18470776PURIFICATION OF TRIMETHYLSILANOLSeptember 2023May 2024Allow810YesNo
18469292OLIGOSACCHARIDE LINKER, LINKER-PAYLOAD COMPRISING THE SAME AND GLYCAN CHAIN-REMODELED ANTIBODY-DRUG CONJUGATE, PREPARATION METHODS AND USES THEREOFSeptember 2023January 2025Allow1621YesNo
18369456HYDROPHILIC LINKERS AND CONJUGATES THEREOFSeptember 2023November 2024Abandon1401NoNo
18368257COMPOSITIONS FOR TREATMENT OF INFLAMMATIONSeptember 2023October 2023Allow100NoNo
18244446FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOFSeptember 2023January 2025Allow1722YesNo
18464646PHARMACEUTICAL FORMULATIONS COMPRISING A PYRIDYLAMINOACETIC ACID COMPOUNDSeptember 2023January 2025Allow1620NoNo
18463707METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FGFR3-RELATED CHONDRODYSPLASIASSeptember 2023November 2024Allow1410NoNo
18463878PHOSPHINE REAGENTS FOR AZINE FLUOROALKYLATIONSeptember 2023February 2025Abandon1711NoNo
18459683COMPOSITIONS CONTAINING DECITABINE, 5AZACYTIDINE AND TETRAHYDROURIDINE AND USES THEREOFSeptember 2023January 2025Abandon1611NoNo
18460428Pyrazolopyridine Derivatives and Uses thereofSeptember 2023May 2024Allow900YesNo
18457567METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORSAugust 2023November 2024Allow1510NoNo
18238721OPHTHALMIC SUSPENSION VEHICLES AND RELATED METHODS FOR PHARMACEUTICAL INGREDIENT DELIVERYAugust 2023January 2024Allow510NoNo
18279078Method of Producing Cellulose CarbamateAugust 2023June 2024Allow910NoNo
18457288ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOFAugust 2023November 2023Allow200NoNo
18454333METHOD FOR EXTRACTING LACTARIUS HATSUDAKE TANAKA POLYSACCHARIDE COMPOUNDAugust 2023February 2024Allow600NoNo
18235867COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH DRUG WASHOUT DUE TO FLUID SECRETIONAugust 2023April 2024Allow810YesNo
18451013LIPID-PEGYLATED COMPOUNDS, PREPARATIONS AND USES THEREOFAugust 2023June 2024Allow1010NoNo
18448277THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOFAugust 2023November 2024Allow1610NoNo
18446522HODGKIN LYMPHOMA THERAPYAugust 2023June 2025Allow2220NoNo
18365920AFFINITY MEDICANT CONJUGATEAugust 2023January 2025Allow1821NoNo
18362028CCR2 RECEPTOR ANTAGONISTS AND USES THEREOFJuly 2023September 2024Allow1310NoNo
18361558HYDROPHILIC ANTIBODY-DRUG CONJUGATESJuly 2023November 2024Allow1601NoNo
18360149LIQUID COMPOSITION COMPRISING GLUCOSEJuly 2023November 2023Allow310YesNo
18359136PROCESS FOR THE MANUFACTURING OF (6AR,10AR)-7-PROPYL-6,6A,7,8,9,10,10A,11-OCTAHYDRO-[1,3]DIOXOLO[4',5':5,6]BENZO[1,2-G]QUINOLINE AND (4AR,10AR)-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDRO-BENZO[G]QUINOLINE-6,7-DIOLJuly 2023February 2025Allow1801NoNo
18225992MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTSJuly 2023April 2025Allow2001YesNo
18357308GRAFT COPOLYMER AND PREPARATION METHOD AND USE THEREOFJuly 2023August 2024Allow1310NoNo
18223652PYRIMIDINE DERIVATIVE AND PREPARATION PROCESS AND USE THEREOFJuly 2023December 2024Allow1710NoNo
18222720EXTRACTION OF ABSCISIC ACID FROM STRAWBERRIESJuly 2023November 2024Abandon1630NoNo
18353556BIOLOGICAL TOTAL JOINT REPLACEMENTJuly 2023January 2024Allow610NoNo
18221516Nicotinamide Mononucleotide Derivatives And Use Thereof In The Treatment And Prevention Of A Red Blood Cell DisorderJuly 2023February 2024Allow710NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1623.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
142
Examiner Affirmed
105
(73.9%)
Examiner Reversed
37
(26.1%)
Reversal Percentile
18.6%
Lower than average

What This Means

With a 26.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
1075
Allowed After Appeal Filing
278
(25.9%)
Not Allowed After Appeal Filing
797
(74.1%)
Filing Benefit Percentile
17.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1623 - Prosecution Statistics Summary

Executive Summary

Art Unit 1623 is part of Group 1620 in Technology Center 1600. This art unit has examined 12,504 patent applications in our dataset, with an overall allowance rate of 60.5%. Applications typically reach final disposition in approximately 29 months.

Comparative Analysis

Art Unit 1623's allowance rate of 60.5% places it in the 14% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1623 receive an average of 1.80 office actions before reaching final disposition (in the 48% percentile). The median prosecution time is 29 months (in the 46% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.